A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma (Q36799900)
Jump to navigation
Jump to search
scientific article published on 15 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma |
scientific article published on 15 July 2015 |
Statements
1 reference
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma (English)
1 reference
Johanna C Bendell
1 reference
Robin K Kelley
1 reference
Kent C Shih
1 reference
Jennifer A Grabowsky
1 reference
Emily Bergsland
1 reference
Suzanne Jones
1 reference
Thomas Martin
1 reference
Jeffrey R Infante
1 reference
Paul S Mischel
1 reference
Tomoo Matsutani
1 reference
Shuichan Xu
1 reference
Lilly Wong
1 reference
Yong Liu
1 reference
Xiaoling Wu
1 reference
Deborah S Mortensen
1 reference
Rajesh Chopra
1 reference
Kristen Hege
1 reference
Pamela N Munster
1 reference
Identifiers
1 reference